A Biorepository to Study Portopulmonary Hypertension

Overview

About this study

We propose to develop a biorepository of plasma samples from patients with suspected and confirmed portopulmonary hypertension to improve our understanding of this disease and its response to pulmonary arterial hypertension targeted therapy and liver transplantation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Critereia:

150 total patients with suspected portopulmonary hypertension in the biorepository, with approximately 75 patients with confirmed portopulmonary hypertension as defined by pulmonary hemodynamics at the time of right heart catheterization

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hilary DuBrock, M.D.

Open for enrollment

Contact information:

Lanmark Pulmonary Clinical Research Unit

(800) 458-0956

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20316207

Mayo Clinic Footer